CloneID: BIWA4
Antigen Long Description: The antibody is the humanized version of the murine BIWA-1.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P16070
Specificity Statement: The antibody is specific for CD44v6. The antibody recognises an epitope encoded by variant exon v6 of CD44. CD44v6 is a tumor associated antigen abundantly expressed in head and neck squamous cell carcinomas (HNSCC) and in normal squamous epithelium.
Application Notes (Clone): The binding affinity of the antibody to CD44v6 was measured by surface plasmon resonance. The antibody showed a specificity of tumor localization when administrated together with another anti-CD44v6 antibody in mice in in vivo experiments (Verel et al. 2002; PMID: 11992408). The specificity of the humanized version of the antibody was confirmed by ELISA anlaysis (Kd= 3.4 nM). The antibody had good therapeutic efficacy, biodistribution and tumor uptake in in vivo experiments in mice. Mice treated with 186Re-BIWA 4 showed a decreased in the tumor volume (US6972324B2). The radioactively labelled humanized version of the antibody was employed in a clinical trial in patients with advanced squamous cell carcinoma of the head and neck showing promising antitumor effects (Börjesson et al., 2003; PMID: 14506195).
English
Deutsch
